<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452322</url>
  </required_header>
  <id_info>
    <org_study_id>IRM 96/17</org_study_id>
    <secondary_id>EK 78a/97Nie1</secondary_id>
    <nct_id>NCT00452322</nct_id>
  </id_info>
  <brief_title>Safety of Testosterone Undecanoate i.m. in Hypogonadal Men</brief_title>
  <official_title>Long-Term Intervention Phase 2 Study of Safety Aspects of Testosterone Undecanoate i.m. in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of male hypogonadism by testosterone substitution has be monitored in terms of&#xD;
      safety. This study relates to safety of a new long-acting preparation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A reliable form of androgen substitution therapy regarding kinetics, tolerance and&#xD;
      restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the&#xD;
      long-acting ester testosterone undecanoate (TU) offers a new modality.&#xD;
&#xD;
      The objective is to assess safety of TU regarding metabolic and pharmacogenetic confounders&#xD;
      in hypogonadal men treated with this new formulation.&#xD;
&#xD;
      This is a longitudinal prospective one-arm open intervention and observation trial. A minimum&#xD;
      of 5 individual assessments is a prerequisite. Investigated modulators of safety parameters&#xD;
      entering regression models are: nadir and/or delta total testosterone concentrations, body&#xD;
      mass index (BMI), and age.&#xD;
&#xD;
      The setting Andrological outpatient department.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate (size, PSA-level)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythropoeisis (Hemoglobin, Hematocrit)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoproteins (HDL, LDL, Triglycerides)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Possible changes of body mass index</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Hypogonadism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Substitution by Testosterone Undecanoate i.m.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men presenting hypogonadism-related symptoms and desiring substitution therapy. Such&#xD;
             symptoms are fatigue, loss of libido, depressiveness, change in body&#xD;
             composition/weight, decreased physical performance, decrease in aggressive behaviour,&#xD;
             disability to cope, decreased work performance, lack of androgenization. At least one&#xD;
             of these symptoms has to be accompanied by low total testosterone levels (&lt; 12 nmol /&#xD;
             L).&#xD;
&#xD;
          -  All patients have to give written informed consent for the use of their data for&#xD;
             scientific evaluation as approved by the Ethics Committee of the Medical Faculty,&#xD;
             University of Muenster, Germany and the State Medical Board.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate Cancer&#xD;
&#xD;
          -  Breast Cancer&#xD;
&#xD;
          -  Desired Paternity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Nieschlag, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Clinics Muenster, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Reproductive Medicine of the University Clinics</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <last_update_submitted>March 26, 2007</last_update_submitted>
  <last_update_submitted_qc>March 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2007</last_update_posted>
  <keyword>Testosterone</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

